impax laboratories

According to a recent report, Piper Jaffray has an optimistic outlook on Impax Laboratories (NASDAQ: IPXL) and continue to see compelling long-term and EPS growth in 2012 after the recent weaknesses surrounding the company. Piper Jaffray maintains an Overweight rating and $33.00 price target on the...

JP Morgan has downgraded Impax Laboratories (NASDAQ: IPXL) from Overweight to Neutral and has lowered the price target from $28 to $26.

Piper Jaffray has raised the price target on Impax Laboratories (NASDAQ: IPXL) from $30 to $33 and maintains its Overweight rating.

Piper Jaffray is reiterating its OW rating and $30 PT on shares of Impax Laboratories Inc. (NASDAQ: IPXL). “We spent time with Impax senior management in meetings with investors, and came away with additional favorable commentary on IPX066 and the depth of the company's generics pipeline,” Piper...

J.P. Morgan is out with its report today on Impax Laboratories (NASDAQ: IPXL), maintaining Overweight. In a note to clients, J.P. Morgan writes, "With positive data in both advancedand naïve Parkinson's patients and 066 licensed to GSK outside of the US, Impax's investment in its branded business...

Goldman Sachs has published a research report on Impax Laboratories (NASDAQ: IPXL) after the company announced positive results from its Phase III study for IPX-066. In the report, Goldman Sachs writes "Positive results in ADVANCE-PD build upon positive results from the APEXPD study, which...

Piper Jaffray is out with its report today on Impax Laboratories (NASDAQ: IPXL), reiterating Overweight after IPXL's IPX066 drug met its primary endpoint in a phase III study. In a note to clients, Piper Jaffray writes, "We believe the results position IPX066 favorably versus adjunctive agents,...

According to J.P. Morgan, it is refining the model for Impax Laboratories (NASDAQ: IPXL) following the 10-K. J.P. Morgan reported that it is not changing the revenue or EPS assumptions. “With Impax operating both generic and specialty pharmaceutical business units, we use a sum-of-the-parts...

Piper Jaffray reports that it hosted a call yesterday with Dr. Alberto Espay, a neurologist focused primarily on Parkinson's disease (PD) who has been involved in studies of IPX066. “Given the positive experience his patients had with IPX066, our expert suggested that it has the potential to be a...

This morning, Piper Jaffray released a report stating that it believes that Impax Laboratories, Inc. (NASDAQ: IPXL) is poised to be one of the top performers in specialty pharma in 2011 in large part due to increasing visibility on its deep generics pipeline (and further progress on the brand...

Piper Jaffray has raised the price target on Impax Laboratories (NASDAQ: IPXL) from $25 to $27 and maintains its Overweight rating.